Efficacy of growth hormone therapy for patients with skeletal dysplasia

Journal of Bone and Mineral Metabolism

Volumn 21, Issue 5, 2003, Pages 307-310

  Kanazawa, Hidemi ^a   Tanaka, Hiroyuki ^a   Inoue, Masaru ^a   Yamanaka, Yoshitaka ^a   Namba, Noriyuki ^a   Seino, Yoshiki ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Achondroplasia; Congenital spondyloepiphyseal dysplasia; Hypochondroplasia pseudoachondroplasia; Schmid type metaphyseal dysplasia

Indexed keywords

GROWTH HORMONE; SOMATOMEDIN C;

ACHONDROPLASIA; ARTICLE; BONE DYSPLASIA; BONE MALFORMATION; CHILD; DRUG INDICATION; FEMALE; GRAVITY; HORMONAL THERAPY; HUMAN; HYPOCHONDROPLASIA; KYPHOSIS; LORDOSIS; MAJOR CLINICAL STUDY; MALE; METAPHYSIS; MUSCLE TONE; OSSIFICATION; PRIORITY JOURNAL; SCOLIOSIS; SHORT STATURE; SIDE EFFECT; SPONDYLOEPIPHYSEAL DYSPLASIA; BODY HEIGHT; BONE DEVELOPMENT; CLINICAL TRIAL; DRUG EFFECT; JAPAN; PATHOPHYSIOLOGY; PRESCHOOL CHILD; TREATMENT OUTCOME;

ACHONDROPLASIA; BODY HEIGHT; BONE DEVELOPMENT; BONE DISEASES, DEVELOPMENTAL; CHILD; CHILD, PRESCHOOL; FEMALE; GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; JAPAN; MALE; TREATMENT OUTCOME;

EID: 0142244524     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-003-0425-7     Document Type: Article

References (10)

1. Seino Y, Moriwake T, Tanaka H, Inoue M, Kanzaki S, Tanaka T, Matsuo N, Niimi H (1999) Diagnosis and growth hormone treatment in achondroplasia. Acta Paediatr 428:118-120
2. Rimoin DL, Lachman RS (1996) Emery and Rioin's Principles and Practice of Medical Genetics, 3rd edn. Churchill Livingstone, London
3. Shiang R, Thompson LM, Zhu YZ, Church DM, Fielder TJ, Bocian M, Winokur ST, Wasmuth JJ (1994) Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78:335-342
4. Suwa S, Tachibana K (1993) Standard growth charts for height and weight of Japanese children from birth to 17 years based on a cross-sectional survey of national data. Clin Pediatr Endocrinol 2:87-97
5. Allen DB, Brook CGD, Bridges NA, Hidmarsh PC, Guyda HJ, Frazier D (1994) Therapeutic controversies: growth hormone (GH) treatment of non-GH-deficient subjects. J Clin Endocrinol Metab 79:1239-1248
6. Ramaswami U, Hindmarsh PC, Brook CG (1999) Growth hormone therapy in hypochondroplasia. Acta Pediatr Suppl 428:116-117
7. Briggs MD, Hoffman SMG, Kings LM, Olsen AS, Mohrenweiser H, Leroy JG, Mortier GR, Rimoin DL, Lachman RS, Gaines ES, Cekleniak JA, Knowlton RG, Cohn DH (1995) Pseudoachondroplasia and multiple epiphiseal dysplasia due to mutations in the cartilage oligomeric matrix protein gene. Nat Genet 10:330-336
8. Disner R, Zaucke F, Kreppel F, Hultenby K, Kochanek S, Paulsson M, Maurer P (2002) Pseudoachondroplasia is caused through both intra- and extracellular pathogenic pathways. J Clin Invest 110:505-513
9. Schlechter NL, Russell SM, Spencer EM, Nicoll CS (1986) Evidence suggesting that the direct growth-promoting effect of growth hormone on cartilage in vivo is mediated by local production of somatomedin. Proc Natl Acad Sci USA 83:7932-7934
10. Rikken B, van Doorn J, Ringrling A, Van den Brande JL, Massa G, Wit JM (1998) Plasma levels of insulin-like growth factor (IGF)-I, II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Horm Res (Basel) 50:166-176